Ruth Coleman

Ruth Coleman has a diverse work experience in various roles and industries. In 2023, they worked as an Investment Manager at Mercia Asset Management PLC. Prior to this, they held the role of Investment Associate at the same company from 2022 to 2023. Ruth also served as a Board Observer at Axis Spine Technologies starting from 2022. In the same year, they became a Board Director at SERG Technologies Ltd and Zedify. From 2018 to 2021, Ruth was the Commercialisation Manager at Grey Innovation Group Pty Ltd, leading the Commercialisation team in new venture identification, due diligence, growth, and operations. Additionally, they worked as a Program Manager at ANDHealth in 2018, managing the ANDHealth+ accelerator program. In 2017 and 2018, they served as a Management Consultant at HealthXL, providing executive consultancy services in the health technology market and advising multinational pharmaceutical and hospital systems. Ruth also worked as a Market Analyst at HealthXL from 2016 to 2017. Ruth started their career as an Investment Analyst in the Healthcare and Pharmaceutical Sector at Trinity Managed Fund from 2014 to 2015. Ruth also gained research experience as a Research Scientist at the Institute of Pharmacology, Georg August University Goettingen in 2015, focusing on investigating Hypertrophy in Human Embryonic Stem Cell Derived Cardiomyocytes.

Ruth Coleman has a diverse education background. Ruth obtained a Master of Science (MSc) degree in Biotherapeutics and Business from the Smurfit Business School & UCD Conway Institute of Biomolecular & Biomedical Research. Prior to that, they completed a Bachelor of Science (BSc) degree in Biomedical Science at Trinity College Dublin. Additionally, Ruth Coleman holds a Leaving Certificate from The Institute of Education. Ruth attended Loreto College Foxrock, although specific details about their degree or field of study at this institution are not provided.